Journal article

Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model

Sai-Wang Seto, Smriti M Krishna, Corey S Moran, David Liu, Jonathan Golledge

CLINICAL SCIENCE | PORTLAND PRESS LTD | Published : 2014

Abstract

Aliskiren is a direct renin inhibitor developed to treat hypertension. Several clinical studies have suggested that aliskiren has beneficial effects on cardiovascular diseases beyond its antihypertensive effect. In the present study, we examined whether aliskiren limits the progression of AAA (abdominal aortic aneurysm), VH (ventricular hypertrophy) and atherosclerosis in an AngII (angiotensin II)-infused mouse model. ApoE-/- (apolipoprotein-E-deficient) mice were infused subcutaneously with AngII (1000 ng/kg of body weight per day; 4 weeks) to induce AAA and VH. At the completion of the AngII infusion, mice were randomly allocated to three groups to receive vehicle control, low-dose aliskir..

View full abstract

Grants

Awarded by Australia Government National Health and Medical Research Council


Awarded by National Heart Foundation, Australia


Funding Acknowledgements

This work was supported by Novartis, the National Health and Medical Research Council and the Office of Health and Medical Research, Australia. S.-W.S. is a recipient of fellowships from the Australia Government National Health and Medical Research Council [grant number 1016349] and from the National Heart Foundation, Australia [grant number PF12B6825]. J.G. is supported by fellowships from the Queensland Government and the National Health and Medical Research Council, Australia.